Home
Trials
Insights
Resources
Webinars
Groups
Courses
Portfolio
A phase III randomized controlled non-inferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) versus piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) - International Journal of Infectious Diseases
The preventive effect of inhaled antibiotic against ventilator-associated pneumonia: A systematic review and meta-analysis - ScienceDirect
So far There were no significant differences between the groups in terms of mortality, length of ICU and hospital stays, and duration of mechanical ventilation (MV).
Pioneer
So far There were no significant differences between the groups in terms of mortality, length of ICU and hospital stays, and duration of mechanical ventilation (MV).